Biotech




Latest Comments
image_pdfimage_print
 

BlueOcean’s founder on astaxanthin – the “next wonder antioxidant”


March 14, 2017
| March 14, 2017 | 1 Comment

Sam Kanes, VP of Strategy and Investor Relations for BlueOcean NutraSciences Inc. (TSXV: BOC) in an interview with InvestorIntel’s CEO […]


BlueOcean in position to tap three huge markets with antioxidant


February 21, 2017
| February 21, 2017

BlueOcean NutraSciences Inc. (TSXV: BOC) announced that it will restart its dormant algae gas infusion subsidiary targeting commercial Omega-3 and […]


 

InvestorIntel Interviews Dr. Zerbe of IntelGenx on Cialis deal


January 09, 2017
| January 09, 2017

In this InvestorIntel interview, Dr. Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. (TSXV: IGX |OTCQX: IGXT), discusses […]


 

IntelGenx CEO speaks to the potential impact of Montelukast on Alzheimers


January 03, 2017
| January 03, 2017

In this InvestorIntel interview, Dr. Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT) […]


IntelGenx takes migraine medication “head-on”


December 22, 2016
| December 22, 2016 | 1 Comment

The term a “bitter pill to swallow” may have been used as a figure of speech since the 17th century, […]


BlueOcean to tap “three huge markets” with the benefits of cannabis and sea


December 14, 2016
| December 14, 2016 | 1 Comment

BlueOcean NutraSciences Inc. (TSXV: BOC) has developed a science-based approach to leverage its current access to 63 retail stores and […]


Bridging Finance Inc.